Intanza® 15 mcg intradermal influenza vaccine elicits cross-reactive antibody responses against heterologous A(H3N2) influenza viruses

Highlights ► Mismatch between vaccine and circulating strains impairs vaccine immunogenicity. ► Intradermal route (ID) of administration has been shown to enhance immunogenicity. ► Intanza® 15 μg is the first licensed ID inactivated split-virion influenza vaccine. ► We evaluated its ability to elici...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Vaccine 2012-04, Vol.30 (18), p.2908-2913
Hauptverfasser:	Ansaldi, Filippo, Canepa, Paola, Ceravolo, Antonella, Valle, Laura, de Florentiis, Daniela, Oomen, Raymond, Vogel, Frederick R, Denis, Martine, Samson, Sandrine I, Icardi, Giancarlo
Format:	Artikel
Sprache:	eng
Schlagworte:	Aged Aged, 80 and over Allergy and Immunology Antibodies, Bacterial - blood Cross Reactions Female Hemagglutination Inhibition Tests Humans Influenza A Virus, H3N2 Subtype - immunology Influenza Vaccines - administration & dosage Influenza Vaccines - immunology Influenza, Human - prevention & control Injections, Intradermal Injections, Intramuscular Male Middle Aged
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Highlights ► Mismatch between vaccine and circulating strains impairs vaccine immunogenicity. ► Intradermal route (ID) of administration has been shown to enhance immunogenicity. ► Intanza® 15 μg is the first licensed ID inactivated split-virion influenza vaccine. ► We evaluated its ability to elicit antibody response against H3N2 circulating viruses. ► Intanza® 15 μg elicited broader antibody responses than IM vaccine in the elderly.
ISSN:	0264-410X 1873-2518
DOI:	10.1016/j.vaccine.2012.02.003